SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 15, 2003; DOI 10.1182/blood-2003-04-1050. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-04-1050v1 102/7/2638    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by De Paepe, P. Articles by Wlodarska, I. Search for Related Content PubMed PubMed Citation Articles by De Paepe, P. Articles by Wlodarska, I. Related Collections Neoplasia Oncogenes and Tumor Suppressors Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 October 2003, Vol. 102, No. 7, pp. 2638-2641 NEOPLASIA Brief report ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma Pascale De Paepe, Mathijs Baens, Han van Krieken, Bruno Verhasselt, Michel Stul, Annet Simons, Bruce Poppe, Geneviève Laureys, Paul Brons, Peter Vandenberghe, Frank Speleman, Marleen Praet, Chris De Wolf-Peeters, Peter Marynen, and Iwona Wlodarska From the Departments of Pathology, Clinical Chemistry, Microbiology and Immunology, and Molecular Diagnostics, Center of Medical Genetics and Pediatric Oncology, Ghent University Hospital, Belgium; the Department of Human Genetics and Flanders Interuniversity Institute for Biotechnology, Division for Morphology and Molecular Pathology, Catholic University of Leuven, Belgium; and the Departments of Pathology, Human Genetics, and Pediatric Oncology, University Medical Center Nijmegen, the Netherlands. We present 3 cases of large B-cell lymphoma (LBCL) with a granular cytoplasmic staining for anaplastic lymphoma kinase (ALK). All of the cases showed striking similarities in morphology and immunohistochemical profile characterized by a massive monomorphic proliferation of CD20-/CD138+ plasmablast-like cells. In one of the cases, initially diagnosed as a null-type anaplastic large cell lymphoma (ALCL), the B-cell phenotype became evident only at recurrence. Fluorescent in situ hybridization (FISH) and molecular studies led to the detection of a CLTC-ALK rearrangement in all 3 cases, without any evidence of full-length ALK receptor expression. The associated t(2;17)(p23;q23) was demonstrated in the karyotype of 2 cases. Although a similar CLTC-ALK aberration was previously identified in ALK-positive T-/null cell ALCL and inflammatory myofibroblastic tumor, its association with ALK-positive LBCL seems to be specific and intriguing. (Blood. 2003;102:2638-2641) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Laurent, C. Do, R. D. Gascoyne, L. Lamant, L. Ysebaert, G. Laurent, G. Delsol, and P. Brousset Anaplastic Lymphoma Kinase-Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis J. Clin. Oncol., September 1, 2009; 27(25): 4211 - 4216. [Abstract] [Full Text] [PDF] S. Prakash and S. H Swerdlow Nodal aggressive B-cell lymphomas: a diagnostic approach J. Clin. Pathol., October 1, 2007; 60(10): 1076 - 1085. [Abstract] [Full Text] [PDF] E. Jacobsen Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type Oncologist, July 1, 2006; 11(7): 831 - 840. [Abstract] [Full Text] [PDF] R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D'Escamard, E. Pellegrino, C. Ponzetto, G. Palestro, et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas Blood, January 15, 2006; 107(2): 689 - 697. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020